Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors

Medical Microbiology and Immunology

Volumn 195, Issue 2, 2006, Pages 65-71

  Sauerbrei, A ^a   Haertl, A ^b   Brandstaedt, A ^a   Schmidtke, M ^a   Wutzler, P ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

Author keywords

Antiviral drugs; Egg model influenza A virus; Neuraminidase inhibitors

Indexed keywords

AMANTADINE; ION CHANNEL; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; EMBRYO; INFLUENZA VIRUS; INFLUENZA VIRUS A; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; ZYGOTE;

ACETAMIDES; AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; CHICK EMBRYO; CHICKENS; ENZYME INHIBITORS; GUANIDINES; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; MICROBIAL SENSITIVITY TESTS; NEURAMINIDASE; OSELTAMIVIR; PYRANS; RIMANTADINE; SIALIC ACIDS; ZANAMIVIR;

EID: 33646681459     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-005-0002-x     Document Type: Article

References (28)

1. Bantia S, Parker CD, Ananth SL, Horn LC, Andries K, Chand P, Kotian PL, Dehghani A, El-Kattan Y, Lin T, Hutchinson TL, Montgomery JA, Kellog DL, Babu YS (2001) Comparison of anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 45:1162-1167
2. Bean WJ, Kawaoka Y, Wood JM, Pearson JE, Webster RG (1985) Characterization of virulent and avirulent A/Chicken/Pennsylvania/83 influenza A viruses: potential role of defective interfering RNAs in nature. J Virol 54:151-160
3. Bolls M, Ridell RJ, Worden AN (1983) Animals and alternatives in toxicity testing. Academic, London
4. Dunn CJ, Goa KL (1999) Zanamivir: a review of its use in influenza. Drugs 58:761-784
5. Farage-Elawar M (1991) Development of esterase activities in the chicken before and after hatching. Neurotoxicol Teratol 13:147-152
6. Fleming DM (2001) Managing influenza: amantadine, rimantadine and beyond. Int J Clin Pract 55:189-195
7. Grunert RR, McGahern JW, Davies WL (1965) The in vivo antiviral activity of 1-adamantan-amine (amantadine). I. Prophylactic and therapeutic activity against influenza viruses. Virology 26:262-269
8. Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355:827-835
9. Haertl A, Sauerbrei A, Stelzner A, Wutzler P (2004) Influenza infection of the embryonated hen's egg - an alternative model for in vivo evaluation of antiviral compounds. Arzneimittelforschung 54:130-134
10. He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471-484
11. Horn M, Vollandt R (1995) Multiple tests und Auswahlverfahren. Gustav Fischer, Stuttgart
12. Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, Yamada M, Suzuki T, Kida H, Kawaoka Y (1997) Differences in sialic acid-galatose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 71:3357-3362
13. Katz JM, Naeve CW, Webster RG (1987) Host cell-mediated variation in H3N2 influenza viruses. Virology 156:386-395
14. McClellan K, Perry CM (2001) Oseltamivir: a review of its use in influenza. Drugs 61:263-283
15. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, Sweet C, Jakeman KJ, Merson J, Lacy SA, Lew W, Williams MA, Zhang L, Chen MS, Bischofberger N, Kim CU (1998) Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42:640-646
16. Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P, Lambkin R (2003) Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect 9:1-14
17. Sauerbrei A, Ulbricht A, Wutzler P (2003) Semi-quantitative detection of viral RNA in influenza A virus-infected mice for evaluation of antiviral compounds. Antiviral Res 58:81-87
18. Schild GC, Oxford JS, De Jong JC, Webster RG (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303:706-709
19. Schmidtke M, Knorre C, Blei L, Stelzner A, Birch-Hirschfeld E (1998) Penetration and antiviral activity of coxsackie virus B3-specific phosphorothioate oligodeoxynucleotides (PS-ODN). Nucleosides Nucleotides 17:1557-1566
20. Sidwell RW (1999) The mouse model of influenza virus infection. In: Zak O, Sande MA (eds) Handbook of animal models of infection. Experimental models in antimicrobial chemotherapy. Academic, San Diego, pp 981-987
21. Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A, Syndergaard T, Kim CU (1998) Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 37:107-120
22. Sidwell RW, Smee DF (2000) in vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 48:1-16
23. Stephen EL, Dominik JW, Moe JB, Spertzel RO, Walker JS (1975) Treatment of influenza infection of mice by using rimantadine hydrochlorides by aerosol and inraperitoneal routes. Antimicrob Agents Chemother 8:154-158
24. Thompson CI, Barclay WS, Zambon MC (2004) Canges in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. J Antimicrob Chemother 53:759-765
25. Tisdale M (2000) Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 10:45-55
26. Watanabe W, Konno K, Ijichi K, Inoue H, Yokota T, Shigeta S (1994) MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents. J Virol Methods 48:257-265
27. Webster RG, Kawaoka Y, Bean WJ, Beard CW, Brugh M (1985) Chemotherapy and vaccination: a possible strategy for the control of highly virulent influenza virus. J Virol 55:173-176
28. Woods JM, Bethell RC, Coates JA, Healy N, Hiscox S, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM, Penn CR (1993) 4-Guanidino-2,4-dideoxy-2,3- dehydro-N-acethyl-neuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 37:1473-1479